Remove 2017 Remove DEA Remove History Remove Programs
article thumbnail

U.S. House Representatives Bonnie Watson Coleman & Cori Bush Unveil Federal Bill to Decriminalize Drug Possession, Replace with Health-Centered Approach

Cannabis Law Report

In addition to eliminating criminal penalties for drug possession at the federal level, the bill also incentivizes state and local governments to adopt decriminalization policies by otherwise limiting their eligibility to receive funds in the Byrne and COPS grant programs. Promotes evidence-based drug education.

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Drug Enforcement Agency (“DEA”). Some physicians and therapists have argued that the Right to Try Act permits them to administer psilocybin to terminally ill patients (since studies are well past the Phase 1 stage), but the DEA has met this with resistance given psilocybin’s status as a Schedule I drug. AIMS Institute, PLLC.

Law 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Congress is About to Lose Its Greatest Cannabis Advocate (Ever)

Canna Law Blog

In 2017, Blumenauer was a co-founder of the Congressional Cannabis Caucus , which continues to drive cannabis policy forward today. He made more history in 2022, when his Medical Marijuana and Cannabidiol Research Expansion Act was signed into law by President Biden.

article thumbnail

World Wide Weed: Risks and Best Practices for Advertising State Legal Cannabis on the Internet

Cannabis Law Report

29 The Department of Justice alleged that Google had “allow[ed] online Canadian pharmacies to place advertisements through its AdWords program targeting consumers in the United States” and that Google specifically assisted the pharmacies in “optimizing their AdWords advertisements, and improving the effectiveness of their websites.”

article thumbnail

Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative @ Harvard

Cannabis Law Report

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. But they remain relatively small, in part because the DEA limits the amount of psilocybin and other psychedelics that can be produced each year.

Law 105
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Lyle Craker, Ph.D., Reddit awarded $82,765.95

article thumbnail

AAFP ( American Academy of Family Physicians) Releases Marijuana, Cannabinoids Position Paper

Cannabis Law Report

Cannabis use, both medically and recreationally, is prevalent throughout history. 6 However, marijuana vaping did significantly increase between 2017 and 2018, mirroring trends in youth tobacco use. 7 While the lifetime use remains relatively stable for this cohort, from 2015-2017, past year and past month use increased 2.7%